32.32
price up icon0.62%   0.20
pre-market  プレマーケット:  32.10   -0.22   -0.68%
loading
前日終値:
$32.12
開ける:
$32.2
24時間の取引高:
998.07K
Relative Volume:
1.07
時価総額:
$2.54B
収益:
$1.55M
当期純損益:
$-258.76M
株価収益率:
-8.2972
EPS:
-3.8953
ネットキャッシュフロー:
$-213.66M
1週間 パフォーマンス:
+9.19%
1か月 パフォーマンス:
+3.13%
6か月 パフォーマンス:
+21.14%
1年 パフォーマンス:
+58.90%
1日の値動き範囲:
Value
$31.41
$32.45
1週間の範囲:
Value
$29.29
$32.45
52週間の値動き範囲:
Value
$19.52
$35.79

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
名前
Celldex Therapeutics Inc
Name
セクター
Healthcare (1107)
Name
電話
908-200-7500
Name
住所
53 FRONTAGE ROAD, HAMPTON
Name
職員
198
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CLDX icon
CLDX
Celldex Therapeutics Inc
32.32 2.52B 1.55M -258.76M -213.66M -3.8953
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.17 114.33B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
614.73 64.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
878.49 54.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
281.90 38.42B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
156.58 34.03B 742.00K -1.37B -1.07B -7.0731

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 アップグレード Barclays Underweight → Overweight
2026-03-23 アップグレード Wolfe Research Peer Perform → Outperform
2025-10-21 開始されました Mizuho Outperform
2025-10-13 開始されました Barclays Underweight
2025-04-28 開始されました Canaccord Genuity Buy
2025-03-20 開始されました Morgan Stanley Overweight
2025-02-13 開始されました UBS Buy
2024-10-07 開始されました Citigroup Buy
2024-09-30 開始されました Goldman Neutral
2024-09-27 ダウングレード Wolfe Research Outperform → Peer Perform
2024-06-18 開始されました Stifel Buy
2024-06-11 開始されました Wolfe Research Outperform
2023-12-20 開始されました TD Cowen Outperform
2023-11-10 アップグレード Wells Fargo Underweight → Equal Weight
2023-08-22 開始されました Wells Fargo Underweight
2021-09-17 開始されました Jefferies Buy
2021-09-10 開始されました SVB Leerink Outperform
2021-07-22 開始されました Guggenheim Buy
2020-02-21 開始されました Cantor Fitzgerald Overweight
2017-08-01 再開されました H.C. Wainwright Buy
2016-11-07 開始されました Aegis Capital Buy
2016-03-08 ダウングレード Jefferies Buy → Hold
2016-03-07 ダウングレード Guggenheim Buy → Neutral
2016-03-07 ダウングレード Leerink Partners Outperform → Mkt Perform
2016-03-07 ダウングレード Wedbush Outperform → Neutral
2016-03-01 開始されました H.C. Wainwright Buy
2015-08-11 繰り返されました Brean Capital Buy
2015-08-11 繰り返されました Oppenheimer Outperform
2015-08-11 繰り返されました ROTH Capital Buy
2015-06-02 繰り返されました WBB Securities Strong Buy
2014-11-17 繰り返されました ROTH Capital Buy
2014-03-04 繰り返されました Oppenheimer Outperform
2013-07-08 繰り返されました Cantor Fitzgerald Buy
2013-03-08 繰り返されました Cantor Fitzgerald Buy
2013-02-26 繰り返されました Oppenheimer Outperform
2013-01-10 繰り返されました Cantor Fitzgerald Buy
2012-10-02 繰り返されました Oppenheimer Outperform
2012-09-14 繰り返されました Cantor Fitzgerald Buy
すべてを表示

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
Jun 14, 2026

Barzolvolimab leaves 64% of CSU patients angioedema-free 7 months after dosing - Stock Titan

Jun 14, 2026
pulisher
Jun 14, 2026

New Celldex antibody depletes mast cells in first human test - Stock Titan

Jun 14, 2026
pulisher
Jun 14, 2026

Celldex reports positive phase 1 data for CDX-622 antibody By Investing.com - Investing.com Canada

Jun 14, 2026
pulisher
Jun 14, 2026

Celldex Presents Positive Phase 1 Results for CDX-622, a Novel Bispecific Antibody for Mast Cell Depletion and TSLP Inhibition at EAACI Annual Meeting - Quiver Quantitative

Jun 14, 2026
pulisher
Jun 14, 2026

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo Finance

Jun 14, 2026
pulisher
Jun 12, 2026

Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus - Sahm

Jun 12, 2026
pulisher
Jun 10, 2026

Celldex to present barzolvolimab, CDX-622 data at EAACI congress By Investing.com - Investing.com Canada

Jun 10, 2026
pulisher
Jun 10, 2026

Celldex to present mast cell targeting drug data at European congress - StreetInsider

Jun 10, 2026
pulisher
Jun 10, 2026

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating - marketscreener.com

Jun 10, 2026
pulisher
Jun 08, 2026

CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 08, 2026
pulisher
Jun 04, 2026

Celldex closes $345 million stock offering - Investing.com

Jun 04, 2026
pulisher
Jun 04, 2026

CLDX News | CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) - ChartMill

Jun 04, 2026
pulisher
May 29, 2026

Wall Street analysts see a 76.42% upside in Celldex (CLDX): Can the stock really move this high? - MSN

May 29, 2026
pulisher
May 27, 2026

Celldex Therapeutics | SCHEDULE 13G/A: Others - Moomoo

May 27, 2026
pulisher
May 26, 2026

Celldex Therapeutics (CLDX) Edges Lower Amid Consolidation Near Key SupportReversal Trade - newsline.com

May 26, 2026
pulisher
May 24, 2026

ELVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

May 24, 2026
pulisher
May 20, 2026

A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $38 to $67 - Moomoo

May 20, 2026
pulisher
May 19, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

May 19, 2026
pulisher
May 15, 2026

Kynam Capital reports 5.84M-share (8.77%) position in Celldex (CLDX) - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Bellevue (CLDX) holds 1.2M shares (1.5%) — files Amendment No.1 - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - Eastern Progress

May 15, 2026
pulisher
May 14, 2026

Celldex Therapeutics stock (US15117B1035): Wells Fargo raises price target to $54 - AD HOC NEWS

May 14, 2026
pulisher
May 14, 2026

Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup - ChartMill

May 14, 2026
pulisher
May 13, 2026

CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Raises Target Price to $54 - Moomoo

May 13, 2026
pulisher
May 12, 2026

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - Yahoo Finance

May 12, 2026
pulisher
May 12, 2026

State Street (CLDX) reports 2.8M shares, 4.2% stake in CELLDex Therapeutics - Stock Titan

May 12, 2026
pulisher
May 11, 2026

The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones - Sahm

May 11, 2026
pulisher
May 09, 2026

LifeSci Capital Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $67 - Moomoo

May 09, 2026
pulisher
May 09, 2026

RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

May 09, 2026
pulisher
May 09, 2026

Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - Sahm

May 09, 2026
pulisher
May 08, 2026

Celldex Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView

May 08, 2026
pulisher
May 08, 2026

12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga

May 08, 2026
pulisher
May 08, 2026

Celldex: Q1 Earnings Snapshot - theheraldreview.com

May 08, 2026
pulisher
May 07, 2026

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 07, 2026
pulisher
May 07, 2026

Celldex filled two late-stage hives trials 6 months early - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K - marketscreener.com

May 07, 2026
pulisher
May 07, 2026

Celldex Therapeutics (NASDAQ: CLDX) widens loss while funding late-stage barzolvolimab trials - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, Vs. FactSet Est of $795K - Moomoo

May 07, 2026
pulisher
May 07, 2026

Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Celldex Reports First Quarter Financial Results and Provides Corporate Update - ChartMill

May 07, 2026
pulisher
May 07, 2026

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial (NASDAQ:CLDX) - Seeking Alpha

May 07, 2026
pulisher
May 06, 2026

FMR LLC reports 5.6% stake in CellDex Therapeutics (CLDX) - Stock Titan

May 06, 2026
pulisher
May 03, 2026

MSN Money - MSN

May 03, 2026
pulisher
May 01, 2026

Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat

May 01, 2026
pulisher
Apr 30, 2026

Asthma Pipeline Enters a New Era of Precision Respiratory Care with 100+ Therapies and 80+ Companies Advancing Next-Generation Biologics and Small Molecules | DelveInsight - Barchart.com

Apr 30, 2026
pulisher
Apr 30, 2026

Celldex earnings on deck as barzolvolimab Phase 3 nears readout By Investing.com - Investing.com Australia

Apr 30, 2026
pulisher
Apr 29, 2026

Vanguard Capital Management (NASDAQ: CLDX) reports 3.45M shares; 5.17% stake - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com UK

Apr 29, 2026
pulisher
Apr 29, 2026

[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Celldex Therapeutics Inc (CLDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Celldex Therapeutics Inc (CLDX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
PEPIN RONALD
SR. VP & CBO
Dec 15 '25
Option Exercise
5.47
19,333
105,714
20,097
Jimenez Freddy A.
SVP & GENERAL COUNSEL
Dec 04 '25
Sale
29.09
4,166
121,210
30,796
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
大文字化:     |  ボリューム (24 時間):